Myopia Progression and the Effect of 7-Methylxanthine

Phase 2 Study of the Effect of 7-Methylxanthine on the Progression of Childhood Myopia

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00263471

Enrollment

Registered

2005-12-08

Start date

2003-10-31

Completion date

2006-03-31

Last updated

2005-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

7-methylxanthine has been shown to increase the concentration and thickness of collagen fibrils in rabbit sclera. Deficient collagen in the sclera may be the cause of progression of childhood myopia. The study hypothesis is that treatment with 7-methylxanthine will stabilize the sclera and prevent further progression of myopia.

Detailed description

Participants are given tablets of 7-methylxanthine 400 mg per day or placebo tablets for 12 months. Axial length, cycloplegic refraction and corneal curvature is measured, as well as weight, height, blood pressure and heart rate. The participants are interviewed about possible CNS, gastrointestinal, or cardiopulmonal side effects.

Interventions

DRUG7-methylxanthine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

8 Years to 13 Years

Healthy volunteers

Inclusion criteria

Children in the age 8-13 years with myopia and an axial growth rate of 0.15 mm or more per year. \-

Exclusion criteria

Severe general ailment (for example diabetes, epilepsy, psychiatric disease) Eye diseases (for example cataract, keratoconus, chronic iritis, glaucoma) \-

Design outcomes

Primary

Measure	Time frame
Axial growth	—

Secondary

Measure	Time frame
Myopia progression	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026